Icecure Medical Ltd
ICCM
Company Profile
Business description
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Contact
7 Haeshel Street
PO Box 3163
Caesarea3079504
ISRT: +972 46230333
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
66
Stocks News & Analysis
stocks
Will Australia’s dwindling fuel supplies impact this share?
Australia’s petrol reserves have dropped from 60 to 35 days.
stocks
US tech stocks sank in Q1 - but the biggest opportunities may be ahead
These 12 undervalued technology stocks look attractive today.
stocks
Before its IPO, OpenAI is already selling to the public
Cathie Wood-led ETFs let the ChatGPT maker reach retail investors without the obligations of going public.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,962.39 | 0.00 | 0.00% |
| DAX 40 | 23,168.08 | 130.81 | -0.56% |
| Dow JONES (US) | 46,666.69 | 162.02 | 0.35% |
| FTSE 100 | 10,436.29 | 71.50 | 0.69% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 22,000.81 | 121.63 | 0.56% |
| Nikkei 225 | 53,413.68 | 290.19 | 0.55% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,611.13 | 28.44 | 0.43% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |